Results 51 to 60 of about 12,705 (162)
Clinical Cardiology, Volume 49, Issue 7, July 2026.Clevidipine and nicardipine demonstrated comparable efficacy and safety for hypertensive emergencies. Clevidipine required lower infusion drug volumes, while subgroup analyses suggested faster attainment of target systolic blood pressure in selected clinical settings.
Tahir Ullah +9 more
wiley +1 more source
Dialysis and Pregnancy: Optimizing Therapy for Best Maternal and Fetal Outcomes
Hemodialysis International, Volume 30, Issue 3, Page 499-507, July 2026.ABSTRACT Pregnancy in women with end‐stage kidney disease (ESKD) requiring dialysis remains high risk, with significant maternal and fetal complications. While fertility rates are markedly reduced in this population, advances in dialysis care and obstetric management have led to increasing reports of successful pregnancies.
Shreepriya Mangalgi, Silvi Shah
wiley +1 more source
ESC Heart FailureAims Patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF) accompanied by significant mitral regurgitation (MR) had poor outcome. Several vasodilator trials showed neutral results.
Shih‐Hung Hsiao +3 more
doaj +1 more source
Advanced Science, Volume 13, Issue 36, 29 June 2026.ABSTRACT The human body functions as a natural reactor for a vast network of chemical and biological reactions and physical interactions among small molecules, proteins, cells, and numerous other components. These reactions/interactions are essential for maintaining normal physiological functions.
Yuhao Cai, Chao Zhao
wiley +1 more source
British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1934-1939, June 2026.Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Parth Narlawar +5 more
wiley +1 more source
Nature Communications, 2019 Hydralazine is a drug used in the treatment of heart failure and cancer, and it has recently been shown to promote lifespan in C. elegans. Here, the authors elucidate the mechanism of action of hydralazine, and show that it targets PKA to promote ...
Esmaeil Dehghan +4 more
doaj +1 more source
A Challenging Twist in Pulmonary Renal Syndrome
Case Reports in Rheumatology, 2014 Case. We report a rare case of hydralazine-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. A 75-year-old African American woman with history of high blood pressure on hydralazine for 3 years presented with acute onset of shortness of ...
Rajaie Namas +3 more
doaj +1 more source
Anti-proliferative Effects of Hydralazine on K562 Cell Line (CML)
Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd, 2017 Introduction: Cancer is the second leading cause of death in the world and among the types of cancer, leukemia is one of the deadliest. Chronic myeloid leukemia (CML) is the best known types of leukemia. Hydralazine is in the cardiovascular medical group,
Sonya Dadakhani +2 more
doaj
Haptenization as the missing link between vasculitis and myeloperoxidase
The Journal of Clinical InvestigationA wide variety of medications can induce adverse immune events and autoimmune responses such as vasculitis. Mechanistically, small molecule drugs known as haptens bind and modify endogenous proteins, triggering such immune reactions. In this issue of the
Laura Santambrogio
doaj +1 more source